Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
7
Recruiting, any sponsor type, condition "Pompe"
By trial status
The same filters, counted in each status. Pick one to switch.
7 trials
Showing 1 to 7, recently updated first.
Denali Therapeutics Inc.Industry
NCT07354724 · 32 participants (planned) · Start May 12, 2026 · Primary completion Aug 2028
Drug: DNL952 · For: Late-onset Pompe Disease
Sites: Irvine, California; St Louis, Missouri; Durham, North Carolina · 8 sites in all
ShionogiIndustry
NCT07123155 · 45 participants (planned) · Start Oct 30, 2025 · Primary completion Aug 8, 2027
Drug: S-606001; Placebo · For: Pompe Disease
Sites: Irvine, California; Gainesville, Florida; Atlanta, Georgia · 28 sites in all
- China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPDRecruiting
Genzyme, a Sanofi CompanySanofi (SNY)
NCT06666413 · 13 participants (planned) · Start May 7, 2025 · Primary completion May 2, 2028
Drug: Avalglucosidase alfa · For: Glycogen Storage Disease Type II; Pompe's Disease
Sites: Shanghai, China
University of California, San FranciscoAcademic, hospital or other
NCT04532047 · 10 participants (planned) · Start Jul 1, 2021 · Primary completion Jul 31, 2031
Drug: Aldurazyme (laronidase) · For: MPS I; MPS II; MPS IVA and 6 more
Sites: San Francisco, California
Amicus TherapeuticsIndustry
NCT06121011 · 500 participants (planned) · Start Feb 16, 2024 · Primary completion Dec 20, 2034
Drug: Cipaglucosidase alfa; Miglustat and 1 more · For: Pompe Disease
Sites: Little Rock, Arkansas; Irvine, California; Jacksonville, Florida · 41 sites in all
- A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18Pivotal-lookingRecruiting
Amicus TherapeuticsIndustry
NCT04808505 · 36 participants (planned) · Start Jul 18, 2023 · Primary completion Jul 2027
Drug: Cipaglucosidase alfa; Miglustat · For: Glycogen Storage Disease Type II Infantile Onset
Sites: Gainesville, Florida; Atlanta, Georgia; Durham, North Carolina · 14 sites in all
- Avalglucosidase Alfa Pregnancy StudyRecruiting
SanofiSanofi (SNY)
NCT05734521 · 100 participants (planned) · Start Oct 26, 2022 · Primary completion Oct 31, 2032
Drug: avalglucosidase alfa-NGPT (GZ402666) IV; avalglucosidase alfa-NGPT (GZ402666) · For: Pompe Disease; Pregnancy
Sites: Bridgewater, New Jersey
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.